Asset 17

SHINE Medical Technologies has partnered with Czech Academy of Sciences to use its method of Lutetium production and is poised to become the second supplier in the United States. Lu-177 is currently being used to treat certain cancers and is in research to learn if the isotope can be used to treat other types. Lu-177 is a beta and gamma emitter with a half-life of approximately 6.5 days making the isotope ideal for therapies. SHINE expects to produce Lu-177 by irradiating ytterbium-176 (not to be confused with yttrium) making it a pure and concentrated isotope with no long-lived metastable elements.



Leave a Reply